Magnetic resonance imaging based rectal cancer classification: Landmarks and technical standardization

Table 1 Upper rectal cancer data

Age	Sex	CCRT	CM	R	L	Pre OP TS	TNM	O/L/R	OP	Post OP TS	TNM
67	M	Y	11	Rb	2	III	T3N+	L	LAR	III	YPT3N1
68	F	Y	11	Rb	2	III	T3N+	O	LAR	III	YPT3N1
56	F	N	11	Rb	2	III	T3N+	L	LAR	III	PT3N1
70	F	N	11	Rb	2	III	T2N+	L	LAR	III	PT3N1
67	F	Y	12	Rb	2	III	T3N+	L	LAR	II	YPT3N0
48	M	Y	12	Rb	2	III	T3N+	L	LAR	II	YPT3N0
49	F	N	12	Rb	2	III	T4N+	O	LAR	III	PT4N1
50	F	N	12	Rb	2	III	T3N+	L	LAR	I	PT1N0
52	M	Y	13	Ra	2	II	T3N0	L	LAR	II	YPT3N0
60	M	N	13	Ra	2	III	T3N+	O	LAR	II	PT3N0
64	M	N	13	Rb	2	III	T3N+	R	LAR	III	PT3N1
74	M	N	13	Rb	2	III	T3N+	L	LAR	III	PT3N1
54	F	N	14	Ra	2	III	T3N+	O	LAR	III	PT3N1
67	M	N	14	Ra	2	III	T3N+	L	LAR	III	PT4N1
63	M	N	14	Ra	1	III	T3N+	L	LAR	II	PT3N0
44	F	Y	15	Rb	2	III	T4N+	O	Hartm.	III	YPT4N1
66	M	N	15	Ra	1	III	T4N+	O	LAR	III	PT3N1
60	M	N	15	Ra	1	III	T3N+	L	LAR	III	PT3N2
73	M	N	15	Ra	1	II	T3N0	R	LAR	II	PT3N0

CCRT: Concurrent chemoradition therapy; R: Rectal Japanese class; L: Level class; OP: Operative; TS: Tumor stage; TNM: Tumor, lymph node, metastasis; O/L/R: Open/laparoscopic, robotic), only M0 tumors were included; LAR: lower anterior resection.

Table 2 Middle rectal cancer data

Age (yr)	Sex	CCRT	CM	R	L	Pre OP TS	TNM	O/L/R	OP	Post OP TS	TNM
64	F	N	7.0	Rb	2	II	T3N0	O	LAR	II	PT3N0
68	F	N	7.0	Rb	2	III	T3N+	O	LAR	II	PT3N0
50	M	Y	7.2	Rb	2	III	T3N+	L	LAR	III	YPT3N2
85	M	Y	7.8	Rb	2	III	T3N+	R	LAR	III	YPT3N1
66	M	N	8.0	Rb	2	III	T3N+	O	LAR	III	PT3N1
73	M	N	8.0	Rb	2	III	T3N+	L	LAR	III	PT3N1
49	M	Y	8.5	Rb	2	III	T3N+	R	LAR	0	YPT0N0
58	M	Y	8.8	Rb	2	III	T3N0	L	LAR	II	YPT3N0
78	M	N	9.0	Rb	2	II	T3N0	L	LAR	III	PT4N1
52	F	N	9.3	Rb	2	III	T3N+	R	LAR	III	PT3N2
61	F	Y	9.5	Rb	2	II	T3N0	L	LAR	III	YPT3N1
73	F	Y	9.5	Rb	2	III	T3N+	R	LAR	II	YPT3N0
48	M	Y	10.0	Rb	2	I	T2N0	R	LAR	I	YPT2N0
74	F	Y	10.0	Rb	2	III	T2N+	R	LAR	II	YPT3N0
47	F	N	10.0	Rb	2	III	T3N+	O	LAR	III	PT3N2
82	M	N	10.0	Rb	2	II	T3N0	L	LAR	II	PT3N0

CCRT: Concurrent chemoradition therapy; R: Rectal Japanese class; L: Level class; OP: Operative; TS: Tumor stage; TNM: Tumor, lymph node, metastasis; O/L/R: Open/laparoscopic, robotic), only M0 tumors were included; LAR: lower anterior resection.

Table 3 Lower rectal cancer data

Age (yr)	Sex	CCRT	CM	R	L	Pre OP TS	TNM	O/L/R	OP	Post OP TS	TNM
51	M	Y	1.0	P	4	III	T4N+	O	APR	III	YPT2N1
57	M	Y	1.0	P	4	III	T3N+	R	ULAR +ISR	0	YPT0N0
49	M	N	1.0	P	4	III	T3N+	O	APR	III	PT4N2
75	M	N	1.3	P	4	II	T3N0	O	APR	I	PT2N0
37	M	Y	2.0	P	4	III	T4N+	O	APR	III	YPT3N1
62	F	Y	2.0	P	4	III	T3N+	O	ULAR +ISR	0	YPT0N0
54	M	N	2.0	P	4	II	T3N0	O	APR	II	PT3N0
48	M	N	2.0	P	4	II	T3N0	O	APR	III	PT3N1
83	F	Y	3.0	P	3	IV	T4N+	O	APR	II	YPT3N0
75	F	Y	3.5	P	2	III	T3N+	R	LAR	0	YPT0N0
54	M	N	3.5	P	3	I	T2N0	R	ULAR + CAA	I	PT1N0
72	M	N	3.7	P	4	III	T3N+	L	APR	III	PT3N2
37	M	Y	4.0	P	3	III	T3N+	L	ULAR + CAA	0	YPT0N0
47	F	Y	4.0	P	2	III	T3N+	L	LAR	0	YPT0N0
60	M	N	4.2	P	2	I	T1N0	L	LAR	I	PT1N0
27	F	N	4.3	P	2	II	T3N0	R	LAR	I	PT2N0
64	F	Y	5.0	P	2	III	T2N+	R	LAR	II	YPT3N0
65	M	N	5.0	P	2	I	T2N0	L	ULAR + CAA	I	PT2N0
37	M	Y	5.5	P	3	III	T3N+	L	ULAR + CAA	III	YPT3N2
71	F	N	5.6	P	2	III	T2N+	R	LAR	I	PT1N0
50	M	Y	5.8	P	3	III	T3N+	R	LAR	III	YPT2N2
40	M	N	6.0	P	2	I	T2N0	L	ULAR + CAA	I	PT2N0
56	M	N	6.0	P	2	I	T2N0	L	LAR	III	PT3N2
44	M	Y	6.1	P	2	III	T3N+	R	ULAR + CAA	III	YPT3N1
56	M	Y	6.3	P	2	III	T3N+	R	LAR	III	YPT3N1

CCRT: Concurrent chemoradition therapy; R: Rectal Japanese class; L: Level class; OP: Operative; TS: Tumor stage; TNM: Tumor, lymph node, metastasis; O/L/R: Open/laparoscopic, robotic), only M0 tumors were included; LAR: lower anterior resection; CAA: Coloanal anastomosis.